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https://doi.org/10.1053/j.gastro.2019.01.034BACKGROUND & AIMS: We performed genetic analyses of a
multiethnic cohort of patients with idiosyncratic drug-induced
liver injury (DILI) to identify variants associated with suscep-
tibility. METHODS: We performed a genome-wide association
study of 2048 individuals with DILI (cases) and 12,429
individuals without (controls). Our analysis included subjects
of European (1806 cases and 10,397 controls), African Amer-
ican (133 cases and 1,314 controls), and Hispanic (109 cases
and 718 controls) ancestry. We analyzed DNA from 113
Icelandic cases and 239,304 controls to validate our findings.
RESULTS: We associated idiosyncratic DILI with rs2476601, a
nonsynonymous polymorphism that encodes a substitution of
tryptophan with arginine in the protein tyrosine phosphatase,
nonreceptor type 22 gene (PTPN22) (odds ratio [OR] 1.44; 95%
confidence interval [CI] 1.28–1.62; P ¼ 1.2  10–9 and repli-
cated the finding in the validation set (OR 1.48; 95% CI
1.09–1.99; P ¼ .01). The minor allele frequency showed the
same effect size (OR > 1) among ethnic groups. The strongest
association was with amoxicillin and clavulanate-associated
DILI in persons of European ancestry (OR 1.62; 95% CI
1.32–1.98; P ¼ 4.0  10–6; allele frequency ¼ 13.3%), but the
polymorphism was associated with DILI of other causes
(OR 1.37; 95% CI 1.21–1.56; P ¼ 1.5  10–6; allele frequency ¼
11.5%). Among amoxicillin- and clavulanate-associated cases of
European ancestry, rs2476601 doubled the risk for DILI among
those with the HLA risk alleles A*02:01 and DRB1*15:01.
CONCLUSIONS: In a genome-wide association study, we
identified rs2476601 in PTPN22 as a non-HLA variant thatassociates with risk of liver injury caused by multiple drugs and
validated our finding in a separate cohort. This variant has been
associated with increased risk of autoimmune diseases,
providing support for the concept that alterations in immune
regulation contribute to idiosyncratic DILI.Keywords: Amino Acid Change; GWAS; Mutation; Inflammation.
diosyncratic drug-induced liver injury (DILI) is a rareIadverse drug reaction that is an important cause of
acute liver failure in the developed world.1,2 DILI typically
occurs in 10 to 20 of 100,000 treated patients, and although
it can lead to death, most cases resolve with discontinuation
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
It is not understood why otherwise safe drugs can rarely
cause drug-induced liver injury (DILI), but mounting
evidence supports inherited, or genetic, susceptibility
factors.
NEW FINDINGS
The largest cohort of DILI patients yet studied revealed
that risk of DILI was associated with a variant in a gene
that has been previously associated with risk for a
variety of autoimmune diseases.
LIMITATIONS
This study did not examine how this new information
could be used to make drugs safer.
IMPACT
These findings add to growing evidence that DILI results
from an immune response to the liver.
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LIVERof the offending drug.3,4 DILI is nonetheless one of the most
frequent complications in the development and approval of
new drugs, often leading to failure in the later stages of drug
development or regulatory actions, including post-
marketing withdrawals.5
A number of genome-wide association studies (GWAS)
on DILI have been performed, leading to the discovery of
significant associations with several human leukocyte anti-
gen (HLA) alleles that are generally drug-specific. For
example, HLA-B*57:01 is associated with DILI in response
to flucloxacillin, HLA-A*02:01 and HLA-DRB1*15:01 are
associated with amoxicillin-clavulanate (AC), HLA-B*35:02
is associated with minocycline, and HLA-A*33:01 is associ-
ated with terbinafine and probably several other drugs as
well.6–9 The association of DILI risk with HLA alleles sup-
ports a role for adaptive immunity in DILI. Although no
confirmed associations outside the HLA region have yet
been identified in a GWAS,10 a trend toward association
with all-cause DILI was recently observed with a single
nucleotide polymorphism (SNP) (rs2476601) in the
PTPN22 gene.7 Because this variant has been associated
with risk for a variety of autoimmune diseases, confirming
this association would provide further support for the im-
mune basis for DILI.
The Drug Induced Liver Injury Network (DILIN), in
collaboration with the International Drug Induced Liver
Injury Consortium (iDILIC), has assembled a cohort of
2048 DILI cases and 12,429 population controls across
three major ethnic populations (European, African Amer-
ican, and Hispanic). After conducting a transethnic meta-
analysis, we replicated our top associated SNPs on an
independent European cohort of cases and performed
multiple subset analyses to investigate their relationship
with known HLA risk alleles for DILI and their effect sizes
within a certain drug or injury type. Here, we confirm a
significant association of DILI risk with rs2476601 in the
PTPN22 gene. This is the first GWAS significant
association outside the HLA region and the first thatappears to hold across many different classes of drugs.
Our finding supports immune mechanisms having a broad
role in DILI.Materials and Methods
We carried out a case/control association study in 3
different populations (European, Hispanic, and African Amer-
ican) and then performed a meta-analysis.
Cases
In the current study, we analyzed 2048 DILI cases due to
multiple causal drugs, including amoxicillin-clavulonate (AC)
and flucloxacillin, collected by the iDILIC and DILIN consortia.
Causality assessment was performed as previously re-
ported.8,11 A total of 1149 European cases were previously
genotyped and analyzed by Urban et al.11 and/or Nicoletti
et al.8 and 899 had undergone GWAS genotyping for the first
time. Supplementary Table 1 shows the breakdown of the case
cohorts by recruitment center, genotyping chip, and ethnicity.
Clinical characteristics of the DILI subjects are reported in
Table 1.
DILIN Cases
A total of 1074 DILIN cases were included, of which 443
DILIN European cases had been previously reported,8,11 and
631 cases, consisting of 389 European, 133 African American,
and 109 Hispanic descendants were newly genotyped.12 The
DILIN protocol and entrance criteria have been previously
published.12 All participants provided written informed con-
sent. Causality assessment was performed as previously
described, and only cases considered probably, highly likely, or
definitely related to the implicated drug were included.13 DNA
was extracted from lymphocytes and stored at the Nationa
Institute of Diabetes and Digestive and Kidney Diseases bio-
sample repository at Rutgers University, Piscataway, NJ.
Genome-wide genotyping for the 564 DILIN cases was per-
formed with the Multi Ethnic Genome Illumina Array at Duke
University and for 32 African American and 35 Hispanic DILIN
cases was performed with the 1Million Illumina duo Array at
Duke University.
iDILIC European Cases
A total of 974 European iDILIC cases with a range of causal
drugs and recruitment phases were included. Of these, 706
cases had been described previously,8,11 and 268 cases due to
flucloxacillin or AC were newly genotyped. The 268 patients
were recruited between May 2009 and May 2013 as a part of
an international collaborative study involving international
recruitment centers. All participants provided written informed
consent, and each study had been approved by the appropriate
national or institutional ethical review boards. The clinical in-
clusion criteria for all cases were those described by Aithal
et al.14 The iDILIC cases were evaluated by application of the
Council for International Organizations of Medical Science scale,
also called the Roussel Uclaf Causality Assessment Method,15
and by expert review by a panel of 3 hepatologists. Only
cases having at least possible causality (score 3) were
included in the study. DNA was prepared as described
Table 1.Clinical Characteristics of the Samples in the 3 Major DILI Case Population
CHARACTERISTICS European n ¼ 1806 Hispanic n ¼ 109 African American n ¼ 133
Clinical information
Mean age, yr 55 41 47
Female, % 56.5 56.8 76.6
Median alanine aminotransferase (range), U/L 774 (9–15065) 843 (20–9108 ) 780 (47–7001)
Median alkaline phosphatase (range), U/L 290 (11–6239) 266 (79–2414) 265 (74–2399)
Median latency (range), d 28 (1–7046) 58 (3–2789 ) 51 (3–935)
Injury Type
Cholestatic (%) 463 (26) 12 (11) 25 (19)
Hepatocellular (%) 747 (41) 73 (67) 80 (60)
Mixed (%) 465 (26) 19(17) 22 (16)
Not available (%) 130 (7) 5(5) 6 (5)
Total 1806 109 133
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Rpreviously.6 Genome-wide genotyping of the additional iDILIC
cases was performed by the Broad Institute, Boston by Infinium
HumanCoreExome BeadChip for 167 cases and by Infinium
Human OmniExpress BeadChip for 101 cases.Clinical Characteristics of the DILI Cases
We collected additional clinical information to further
investigate the relevance of the most significant associations.
Time from start of medication to DILI recognition, concomitant
medications, and maximum serum levels of alkaline phospha-
tase (ALP) and alanine aminotransferase (ALT) were available
for both DILIN and iDILIC cases. Also available on all cases was
whether the injury was hepatocellular, cholestatic, or mixed
(based on the initial R value).15 Specific diagnosis of autoim-
mune diseases was recorded for iDILIC cases, while DILIN cases
included reports on whether patients had a general history of
autoimmune/collagen vascular disease (Yes/No).Controls
As DILI has a very low incidence, we consider that a large
set of general population control samples can overcome the
potential bias of inclusion of people who may have experienced
unrecorded DILI events. A total of 10,397 European controls
described in our previous study8 were used. Moreover, data for
1314 African American and 718 Hispanic controls were ob-
tained from the MESA study (phs000420.v6.p3) in dbGAP.16
Supplementary Table 1 also shows the breakdown of the con-
trol cohorts by genotyping chip and ethnicity.Genetic Analysis
Quality control checks on the initial genotype data were
performed as summarized in the Supplementary Materials and
Methods. EIGENSTRAT analysis was used to identify the
European, African-American, and Hispanic cohorts. Our final
sample sizes were 1806 cases and 10,397 controls of European
ancestry, 133 cases and 1314 controls of African American
ancestry, and 109 cases and 718 controls of Hispanic ancestry.
SNP imputation was performed in batches dividing the samples
according to ethnicity and genotyping platforms. For each
batch, imputation was carried out using the Michigan Imputa-
tion Server,17 as described in the Supplementary Materials andMethods. For HLA genotypes, 4-digit HLA alleles were inferred
using HIBAG.18
Association analyses were performed using logistic regres-
sion under the additive model in Plink.19 EIGENSTRAT axes
were used as covariates. A meta-analysis of the 3 ethnic groups
was performed using GWAMA fixed effects. Variants that (1)
had a concordant effect in at least 2 of the ethnic groups and
that (2) showed final meta P values below 5  10–8 were
considered statistically significant.20,21 The top associated
imputed SNPs were genotyped in the available cases using a
TaqMan SNP genotyping assay (ThermoFisher Scientific, Wal-
tham, MA) in accordance with the manufacturer’s
recommendations.
Multimarker association analysis among the combinations
of carriage groups of known HLA risk alleles and the PTPN22
variant allele was performed by logistic regression using
principal component as covariates and considering the joint
negative carriers as the reference group in the drug-specific
cohorts (such as AC, flucloxacillin, terbinafine, and flupirtine).
Moreover, after transforming the quantitative clinical variables
(latency, maximum ALP, and maximum ALT) to improve
normality, we applied a linear regression model to test differ-
ences among known HLA risk alleles and PTPN22 variant in the
AC cohort.
Epistasis analysis was performed by logistic regression,
using principal component axes as covariates and considering
an interaction term between being a carrier of any HLA risk
alleles and being a carrier of the associated variant.
We also performed association analysis between the
PTPN22 variant and reported clinical variables. First, we
treated latency and other clinical variables as a quantitative
trait. After transforming the quantitative variables to improve
normality, we applied a linear regression model to test PTPN22
variant effect on clinical trait in a cases-only design. Epistasis,
multimarkers, and multinomial logistic regression analyses
were carried out using STATA15 (Stata Corp, College Station,
TX).Icelandic DILI Replication Cohort
An independent Icelandic DILI replication cohort was
recruited at the National University Hospital of Iceland. The
Icelandic DILI cases were evaluated in accordance with iDILIC
causality assessment criteria.8 Clinical characteristics of the
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The cohort included 113 DILI cases and 239,304 population
controls. Geneotyping data from the Icelandic sample set was
imputed as previously described.22–24 HLA alleles were also
imputed by Graphtyper.25 Logistic regression under an additive
model was used to test for association between variants and
DILI. Detailed description of Icelandic analyses is reported in
the Supplementary Materials and Methods.Results
Overall Findings
Our final meta-analysis included 3,622,749 SNPs in 2048
cases and 12,429 controls (see QQ plots in Supplementary
Figure 1). Clinical characteristics of the well-phenotyped
DILI cases across 3 main ethnicities are reported in
Table 1. We identified a significant association with
rs2476601 (chr1:114377568>A/G), a polymorphism
changing tryptophan to arginine at codon 620 of PTPN22
(odds ratio [OR] 1.44; 95% confidence interval [CI] 1.28–
1.62; P ¼ 1.2  10–9; Figure 1). The enrichment was
observed across all ethnic groups analyzed in our study,
although the low number of African American and Hispanic
cases limited the power to identify a significant association
for variants with an OR < 2 (Table 2). Similar ORs were also
evident within subgroups of European ancestry
(Supplementary Table 3). Independent genotyping of
available DILIN cases across ethnicities (N ¼ 1070)
confirmed the GWAS genotypes for rs2476601 with a
concordance rate of 100% (Supplementary Table 4).
rs2476601 was also found to increase the risk of DILI in the
independent Icelandic replication cohort (allele frequency
[AF] ¼ 0.13 in 113 cases vs 0.09 in 239,304 controls),
having an effect size that was comparable to that of the
discovery cohort (OR 1.48; 95% CI 1.09–1.99; P ¼ .01).In addition to rs2476601, several variants in the MHC
region were found to have genome-wide significant
P values, led by rs3129880 (OR 1.48; 95% CI 1.36–1.60;
P ¼ 1.2  10–20). This variant is a proxy of HLA-
DRB1*15:01 (r2 ¼ 0.56) consistent with the large number
of AC DILI cases in the cohort. As expected based on in-
clusion of 195 flucloxacillin and 444 AC European DILI
cases, the most significant HLA risk alleles were HLA-
B*57:01, followed by HLA-DRB1*15:01 (OR 2.19; P ¼
1.4  10–18, see Table 2). Unlike the rs2476601 association,
HLA association signals were specific for the European
population in which flucloxacillin and AC cases were the
most abundant.
Subsequent genome-wide conditional analysis incorpo-
rating the genotypes of the 4 well-established DILI HLA risk
alleles (HLA-B*57:01, HLA-DRB1*15:01, HLA-A*02:01 and
HLA-A*33:01)6–8 as covariates was undertaken to identify
novel independent risk factors. The analysis revealed that
rs2476601 remained the most significant independent risk
variant (OR 1.45; 95% CI 1.30–1.64; P ¼ 7.6  10–10,
Figure 1B and Supplementary Table 5). Similarly, the inde-
pendence between rs2476601 and the main HLA risk alleles
was confirmed in the Icelandic cohort in a multivariate
regression model (OR 1.54; P ¼ .013; Supplementary
Table 6). When controlling for the 4 major known DILI
HLA risk alleles, HLA-C*04:01 was the most significant in-
dependent HLA allele associated with DILI risk reaching
near statistical significance when corrected for the total
number of imputed HLA alleles (OR 1.21; 95% CI 1.09–1.37;
P ¼ 6.3  10–4). HLA-C*04:01 association showed consis-
tent trends across all three ethnicity groups (European P ¼
.004, OR 1.19; African American P ¼ .02, OR 1.42; Hispanic
P ¼ .53, OR 1.13, Supplementary Table 7). Data for indi-
vidual drugs in relation to this risk association are shown in
Supplementary Table 8. It is notable that the greatestFigure 1.Manhattan plot
displaying the association
results of (A) the meta-
analysis among the 3 ma-
jor populations (European,
African American, and
Hispanic) and (B) the
meta-analysis after condi-
tioning on the 4 main
known HLA DILI risk al-
leles among the 3 major
populations (European,
African American, and
Hispanic). The results are
reported for variants that
had a consistent effect in
Europeans and at least 1
of the 2 additional pop-
ulations. SNPs shown in
green have a significance
level less than 5  10–6
and red have a signifi-
cance level less than 5 
10–8.
May 2019 PTPN22 Variant in DILI 1711association was seen with the 58 cases in whom DILI was
attributed to herbal and dietary supplements (OR 2.24,
P ¼ .0008, individual agents listed in Supplementary
Table 9).
We also found that rs72631546, an intergenic marker on
chromosome 2, was the third most significant variant (OR
1.84; P ¼ 1.2  10–7; Table 2). rs72631546 is in LD (r2 ¼
0.5) with rs72631567, which was an SNP previously sus-
pected to be associated with DILI risk.8 The rs72631546
association was consistent between European and Hispanic
individuals (OR 1.79, P ¼ 1.9  10–6; OR 2.07, P ¼ .003,
respectively) and was independent of the known HLA risk
associations (OR 1.87, P ¼ 6.0  10–8).CL
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RAssociation With PTPN22 rs2476601
In the European cohort, the AC cases showed the most
significant association with rs2476601 (OR 1.62; 95% CI
1.32–1.98; P ¼ 4.0  10–6) with higher frequency than
European controls (AF ¼ 0.13 vs AF ¼ 0.08, respectively).
We also found evidence that the association was consistent
among the remaining of European DILI cases (n ¼ 1362; OR
1.37; 95% CI 1.21–1.56; P ¼ 1.5  10–6, AF ¼ 0.11;
Supplementary Figure 2), and it did not appear to be driven
by particular drugs or categories of drugs (Table 3). Sig-
nificance of P  .05 was seen for cases due to several causal
drugs including sulfamethoxazole-trimethoprim (P ¼ .01)
and terbinafine (P ¼ .01). On the other hand, cases related
to drugs such as flucloxacillin and diclofenac, which were
well represented in the cohort as causal agents, showed
smaller increases in minor AF compared with controls,
which were not statistically significant (P > .05). We also
evaluated the relationship of rs2476601 genotype to DILI
phenotype. Of our European ancestry cases, 45% had a
hepatocellular pattern of injury, and 55% were cholestatic
or mixed. We found enrichment compared with controls for
rs2476601 in both injury patterns, with similar AF and ORs
(hepatocellular AF ¼ 0.12, OR 1.38, P ¼ .0001; cholestatic/
mixed AF ¼ 0.13, OR 1.50, P ¼ 6.5  10–8; Supplementary
Table 10). We also found that there was a trend for the
frequency of rs2476601 to be higher in the DILI cases most
confidently ascribed to the implicated drug (SupplementaryTable 2.Summary Statistics for the Univariate Transethnic Met
Marker
All Euro
OR 95%CI P OR 95%CI
rs2476601 1.44 1.28–1.62 1.2  10–9 1.42 1.27–1.60
rs72631546 1.84 1.47–2.31 1.2  10–7 1.79 1.41–2.27
rs3129880 1.48 1.6–9.32 1.2  10–20 1.56 1.44–1.69
HLA-B*57:01 2.19 1.84–2.61 1.40  10–18 2.24 1.94–2.6
HLA-DQB1*03:03 1.67 1.41–1.99 7.48  10–9 1.69 1.46–1.96
HLA-DRB1*15:01 1.37 1.22–1.53 1.03  10–7 1.40 1.27–1.54
HLA-C*06:02 1.40 1.23–1.59 1.88  10–7 1.45 1.3–1.62
HLA-DQB1*06:02 1.31 1.17–1.46 1.47  10–6 1.40 1.27–1.55
ORs, 95% Cis, P values are presented after correcting for popu
population.Figure 2). We found that there was no significant association
between rs2476601 and time of onset of DILI relative to
starting treatment with the implicated drug as well as
maximum ALP or maximum ALT values.Assessment of Correlation With Autoimmune
Diseases
As rs2476601 has been previously associated with
numerous autoimmune diseases,26 we investigated whether
the presence of autoimmune diseases in our DILI cohort
could have contributed to the associations observed. We
identified 567 DILI subjects with evidence of autoimmune
diseases; 135 of whom had a documented history of auto-
immune/collagen vascular disease, and the remaining sub-
jects were suspected to have an autoimmune disease
because they had been treated with at least 1 drug
commonly used in these conditions, usually in addition to
the agent implicated as causing DILI (list of potential auto-
immune treatments is presented in Supplementary
Table 11). When all 567 samples with known or sus-
pected diagnosis of autoimmune disease were excluded
from our cohort, the rs2476601 association remained highly
significant with the same effect size (n ¼ 1245; OR 1.40;
95% CI 1.23–1.60; P ¼ 6.4  10–7, Supplementary
Table 12).Assessment of Correlation With Known HLA Risk
Alleles
We found an enrichment of rs2476601 among European
DILI cases due to causal drugs known to have HLA alleles as
the main genetic risk association (eg, flucloxacillin, terbi-
nafine, fenofibrate, minocycline, sertraline, AC) compared
with the rest of the cases (OR 1.52 vs OR 1.38,
Supplementary Table 13). Among these drugs associated
with HLA risk alleles, AC was the major causal drug (444
cases) and showed the strongest association with
rs2476601 (OR 1.62; 95% CI 1.32–1.98; P ¼ 4.0  10–6).
AC-drug specific conditional analysis on HLA-A*02:01 and
HLA-DRB1*15:01 confirmed that rs2476601 was an inde-
pendently associated risk factor from the known HLA riska-analysis of Genome-Wide Associated Variants
pean African American Hispanic
P OR 95%CI P OR 95%CI P
9.6  10–10 1.94 0.73–5.18 .19 1.91 0.94–3.89 .07
1.92  10–6 — — — 2.07 1.27–3.36 .003
5.09  10–26 0.92 0.67–1.27 .62 0.97 0.68–1.4 .89
4.53  10–27 1.64 0.36–7.4 .52 0.72 0.17–3.02 .65
1.27  10–12 — — — 0.97 0.29–3.16 .95
3.19  10–11 0.85 0.43–1.69 .65 1.16 0.68–1.99 .58
6.47  10–11 0.92 0.58–1.48 .74 1.38 0.77–2.48 .28
3.15  10–11 0.90 0.66–1.21 .48 1.11 0.64–1.91 .72
lation stratification with EIGENSTRAT axes within each major
Table 3.Association With rs2476601 for Drugs With at Least 3 Case Carriers in the European Cohort and OR >1
Drugs No. cases AF OR 95% CI P
Amoxacillin/Clavulanic acid 444 0.13 1.62 1.32–1.98 .000004
Terbinafine 15 0.20 3.23 1.29–8.1 .01
Sulfamethoxazole/Trimethoprim 42 0.17 2.07 1.16–3.71 .01
Methotrexate 9 0.22 3.34 1.09–10.16 .03
Rofecoxib 6 0.25 4.08 1.05–15.82 .04
Valproic acid 16 0.18 2.43 0.99–5.95 .05
Flupirtin 6 0.25 4.43 0.98–20.05 .05
Fenofibrate 10 0.20 2.93 0.97–8.87 .06
Erythromycin 11 0.18 2.89 0.95–8.78 .06
Doxycycline 6 0.25 3.21 0.85–12.1 .09
Pravastatin 6 0.25 3.21 0.83–12.47 .09
Nimesulide 20 0.12 2.10 0.81–5.41 .12
Cefuroxime 4 0.25 3.45 0.69–17.28 .13
Ethinylestradiol/Levonorgestrel 7 0.21 2.53 0.71–9.05 .15
Isoniazid 43 0.13 1.59 0.84–3.02 .16
Celecoxib 9 0.17 2.37 0.69–8.19 .17
Flucloxacillin 195 0.11 1.24 0.90–1.71 .18
Nitrofurantoin 74 0.12 1.40 0.85–2.32 .19
Piroxicam 5 0.20 2.85 0.60–13.68 .19
Gabapentin 5 0.20 2.79 0.58–13.39 .2
Cefazolin 21 0.14 1.59 0.67–3.8 .3
Mercaptopurine 10 0.15 1.72 0.50–5.97 .39
Imatinib 8 0.12 1.70 0.38–7.56 .49
Ticlopidine 5 0.10 2.01 0.24–16.73 .52
Atorvastatin 29 0.10 1.32 0.56–3.09 .53
Minocycline 32 0.11 1.29 0.58–2.86 .53
Interferon Beta-1a 4 0.12 1.90 0.21–16.79 .57
Amiodarone 5 0.20 1.64 0.28–9.73 .59
Diclofenac 66 0.10 1.17 0.67–2.04 .59
Ibuprofen 15 0.10 1.36 0.41–4.52 .62
Herbal and dietary products 58 0.10 1.19 0.65–2.17 .58
Disulfiram 8 0.12 1.40 0.32–6.13 .65
All other therapeutic products 9 0.11 1.33 0.30–5.93 .71
Nicotinic acid 4 0.12 1.45 0.17–12.17 .73
Lisinopril 5 0.10 1.45 0.17–12.17 .74
Phenytoin 10 0.10 1.18 0.27–5.11 .82
Rosuvastatin 4 0.12 1.27 0.14–11.29 .83
Sertraline 6 0.08 1.17 0.15–9.27 .88
Levofloxacin 17 0.09 1.05 0.32–3.44 .94
Drug results are ordered by P value. In bold are drugs previously known to be associated with at least 1 HLA risk allele.
No. cases, number of cases for each drug; P, logistic P value.
1712 Cirulli et al Gastroenterology Vol. 156, No. 6
CLINICAL
LIVERalleles (OR 1.6 and P ¼ 8.9  10–6, Supplementary Table 5).
Because the 3 markers were independent among each other,
we looked for evidence of co-occurance of rs2476601 and
the known HLA risk alleles. We therefore stratified AC cases
and controls based on HLA allele carriage (Supplementary
Table 14). There was evidence that carriers of rs2476601
were enriched in AC DILI patients who carried one or both
the HLA. In agreement with this finding, multimarker anal-
ysis on the AC cohort confirmed that when rs2476601 co-
occurred with either of the 2 HLA alleles, this consistently
enhanced the association with DILI risk by almost 2-fold
compared with risk associated with the HLA alleles alone
or in combination (Table 4). Joint carriage of the 3 markers
was associated with a 13-fold higher DILI risk compared
with the negative carriers. We had only 12 AC cases carryingonly rs2476601 and neither of the 2 HLA risk alleles. This
limited number did not allow us to capture the association
of rs2476601 alone with AC DILI risk, but the 95% CI re-
ported in Table 4 included an OR of 1.5 . Moreover, when we
compared the triple positive carrier against HLA-A*02:01
and HLA-DRB1*15:01 positive but rs2476601 negative
group we found a significant 1.7-fold increase in the asso-
ciation with DILI risk (OR 1.8; 95% CI 1.24–2.60; P ¼ .002).
This confirmed that rs2476601 is independently associated
with AC DILI risk. Finally, we tested the presence of a SNP-
HLA interaction effect for AC DILI. The analysis showed that
there was an epistatic effect between rs2476601 and the
presence of at least one of the HLA risk alleles (OR 1.9; P ¼
.05). In other words, the joint effect of one or both HLA risk
alleles and rs2476601 was more than additive.
Table 4.Summary Statistics of the Multimarker Analysis Performed on the Carriage of HLA-DRB1*15:01, HLA-A*02:01 and
rs2476601 in the European Amoxicillin-Clavulanate-related DILI Cohort
Carriage group
Cases Controls
OR 95% CI Pn CF n CF
þ/þ/þ 49 0.11 187 0.02 13.80 9.18–20.71 1.1*10–36
/þ/þ 35 0.08 625 0.06 3.03 1.99–4.63 2.3*10–7
þ//þ 12 0.03 206 0.02 3.28 1.74–6.19 2.5*10–4
//þ 12 0.03 663 0.07 0.95 0.51–1.77 .8
þ/þ/ 126 0.28 895 0.09 7.68 5.63–10.48 8.8*10–38
/þ/ 101 0.23 3212 0.31 1.68 1.23–2.30 1.1*10–3
þ// 41 0.09 1037 0.10 2.09 1.41–3.11 2.7*10–4
// 68 0.15 3531 0.34 — — —
ORs, 95% Cis, and P values are presented after correcting for population stratification and considering the triple negative
carriers as the reference group. The 3 letters in the first column (carriage group) reflects in order the HLA-DRB1*15:01 status,
the HLA-A*02:01 status, and the rs2476601 status. The risk alleles status is represented by “þ” ¼ present or “–“ ¼ absent.
CF, carriage frequency; n, number of samples in the group.
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and flupirtine cohorts also supported rs2476601 as inde-
pendently associated with DILI risk, showing consistent ORs
in DILI due to flucloxacillin (OR 1.3), terbinafine (OR 3.4),
and flupirtine (OR 2.5) in addition to the enhanced the DILI
risk associated with the known HLA alleles (Supplementary
Table 15). We also examined whether subjects in the AC
cohort who carried any combination of the 3 risk alleles
differed in clinical phenotype (see Materials and Methods)
from each other or from individuals not carrying any of the
3 alleles. No differences were apparent.Discussion
Here, we report the results of the largest DILI GWAS to
date based on 2048 DILI cases and 12,429 controls. Our
analyses identified a robust association with a variant in
PTPN22, a tyrosine phosphatase that has been linked to
numerous autoimmune disorders.26 In addition, the associ-
ation was not limited to a certain drug or pattern of injury,
instead showing associations across the entire cohort.
Moreover, we showed that the PTPN22 variant added to the
DILI risk associated with known HLA alleles, increasing the
association with AC DILI risk almost 2-fold and appearing to
have a similar effect on other DILI events with known HLA
risk alleles. This finding provides new insights into DILI
etiology and highlights the potential role of non-HLA vari-
ants in immune-related genes as risk factors for DILI across
a broad spectrum of causal drugs.
rs2476601 is associated with increased risk of type 1
diabetes mellitus, rheumatoid arthritis, systemic lupus ery-
thematosus, vitiligo, and Graves’ disease, among others, but
is also associated with decreased risk of Crohn’s disease and
Behçet disease.26 This is the first confirmed genome-wide
association with DILI risk that lies outside the MHC locus
and is the first variant that appears to generally predispose
to DILI as opposed to DILI due to specific drugs. The
replication of the association in separate Icelandic cases and
controls where the PTPN22 variant is relatively common
confirmed the association.Our previous study also suggested that rs2476601 might
be associated with risk for DILI, but the variant did not meet
the criteria for genome-wide significance.7 The present
study confirmed that association, and with a larger sample
size the strength of the association exceeded the required
statistical threshold for a variant of this moderate effect size.
It should be noted that the effect size seen for this variant
with DILI was similar to those seen for other disease con-
ditions in which rs2476601 is associated with increased
risk.27 The frequency of rs2476601 varies greatly from
population to population, being as high as 15% in Finnish
individuals and as low as <0.01% in East Asian in-
dividuals.28 Here, we found that the frequency of the variant
in DILI cases was higher in each population studied relative
to the frequency in a matched control population, with the
OR remaining similar among different ethnic and racial
populations. Despite this consistency of the OR, the rela-
tively small effect size of this variant means that larger
sample sizes are needed to confirm the associations as real
in all populations and with different agents responsible for
causing DILI. The largest subset of the current study was
Northern European individuals (n ¼ 1107 cases and 5090
controls), in whom a very strong signal for this variant was
seen (P ¼ 3.6  10–6, OR 1.41, Supplementary Table 3). The
other analyzed ethnicities, which had much smaller sample
sizes, did not produce P values below .05 despite their
similar ORs for the effect of this variant.
Because patients with autoimmune disease may take
more medications than others, there was a possibility that
the association we observed with rs2476601 could actually
be due to an increased prevalence of autoimmune diseases
in DILI patients. To address this possibility, we identified
cases with a recorded or suspected (based on concomitant
medications) diagnosis of autoimmune diseases. Although
rs2476601 in these patients had a slightly higher effect size,
the association remained comparably strong even among
patients not known or suspected to have underlying auto-
immune conditions. Because history of autoimmune dis-
eases was not systematically collected in all subjects, and
because patients with autoimmune diseases may not be
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of the DILI event, we cannot rule out the possibility that
some of our DILI patients had undiagnosed and untreated
autoimmune conditions.
The association with rs2476601 was consistent across
various phenotypes in our cohort, including injury patterns
(cholestatic or mixed vs hepatocellular), causal drugs, and
strength of causality assessment. However, we did not find
any association with other features, including DILI latency.
We found that AC cases and other cases with the highest
causality scores tended to have the highest frequencies for
rs2476601. As DILI is a diagnosis of exclusion, it is un-
avoidable to have some uncertainty about the true cause of
liver injury in certain patients, and so for real risk associa-
tions, we expect to see the strongest associations in those
cases with the highest causality score. In our cohort, most
AC cases were classified as having a high likelihood of DILI
since the AC-DILI characteristic phenotypes have been well
defined.29 The higher allele frequency in AC cases likely
reflects a higher proportion of patients who truly have DILI
due to this drug. However, there may be an AC-specific
genetic effect of rs2476601, as AC cases had a higher
allele frequency than did other DILI cases even when
restricting to the same causality probability categories.
Our analysis showed that rs2476601 appears to be
associated with DILI risk regardless of which HLA alleles are
associated with DILI risk. This is also the case with auto-
immune diseases in which rs2476601 is associated across
diseases that are themselves associated with different HLA
alleles.26 This effect is consistent with the fact that PTPN22
controls events downstream from HLA presentation of
neoantigen as summarized in Burn et al.30 PTPN22 encodes
lymphoid protein tyrosine phosphatase (Lyp), which is
expressed exclusively in immune cells. Although the mech-
anisms whereby the rs2476601 variant reduces immune
tolerance are not clear, Lyp is involved in T-cell receptor
signaling, acting at several intermediate points in the
signaling cascade. Lyp also appears to influence regulatory
T-cell function. Considerable data now support the concept
that DILI can result from a T-cell–mediated immune attack
on the liver, presumably directed at HLA-presented neo-
antigens. This response may be initiated relatively
frequently during treatment with drugs capable of causing
DILI. However, clinically important liver injury does not
occur in most of these patients because immune tolerance is
activated.31,32 We therefore suggest that rs2476601 pre-
disposes to DILI by reducing immune tolerance. Our finding
supports this hypothesis, because we found a significant
genetic interaction effect among HLA risk alleles and
rs2476601, detecting that the AC DILI risk associated with
the joint carriage of HLA risk alleles and the variant is more
that the sum of the risks associated with each single risk
factor. Most of the currently reported associations for other
diseases and the PTPN22 variant also show HLA associa-
tions, particularly HLA class II associations which is
consistent with the strong association seen with AC-DILI but
only a slightly increased frequency of the variant with
flucloxacillin-DILI in which the associated allele is class I.
Moreover, the increased frequency of the rs2476601 variantin DILI cases where there was no apparent HLA association
suggests the possibility of other HLA risk alleles yet to be
discovered and/or a potential role for PTPN22 in non–T-
cell–mediated forms of DILI in which other immune cells
might be involved.
Although the association with rs2476601 was robust, its
effect size was modest. The OR averaged approximately 1.3
in the various ethnic groups identified here. However, in the
10% of the subjects who also carried the 2 known HLA risk
alleles (HLA-A*02:01 and HLA-DRB1*15:01), the risk of DILI
due to AC was increased more than 13-fold. Given the rarity
of serious liver injury due to AC, despite its widespread use,
genotyping for risk management is probably not realistic.
There may be instances when genotyping for this variant
together with the identified HLA risk alleles could improve
confidence in the causality assessment but this testing is not
currently commercially available to our knowledge. It also
should be noted that with drugs causing more frequent and
severe liver injury, genotyping to identify 10% of a patient
population at 13-fold increased risk of DILI might be
reasonable.
In addition to the rs2476601 association, we also found
evidence for a novel independent HLA risk factor in HLA-
C*04:01. This association is interesting as the allele may
be a risk factor across ethnicities and ADR clinical pheno-
types. In fact, HLA-C*04:01 has previously been shown to be
associated with nevirapine hypersensitivity in a Malawian
population,33 and in our cohort, the association was
concordant across all three populations (Supplementary
Table 8) and across multiple drugs and herbal prepara-
tions (Supplementary Table 7).
In conclusion, we have identified the variant rs2476601
in the PTPN22 gene as the first robust genetic risk associ-
ation for DILI lying outside the MHC region. In addition, this
association is the first to be associated across a broad range
of implicated drugs and across different ethnic backgrounds.
rs2476601 is therefore the first identified general risk as-
sociation for DILI. The prior well-established association of
this polymorphism with the risk of autoimmune diseases
broadens the role of the immune system in DILI pathogen-
esis and may help inform future treatment and prevention
efforts.
Appendix
Collaborators and Contributors to case
recruitment
iDILIC investigators (in alphabetical order).
Guruprasad P. Aithal, National Institute for Health Research
(NIHR) Nottingham Digestive Diseases Biomedical Research
Unit, Nottingham University Hospital NHS Trust and Uni-
versity of Nottingham, Nottingham, UK; Raul J. Andrade,
IBIMA Hospital Universitario Virgen de la Victoria, Uni-
versidad de Málaga, Málaga, Spain and CIBERehd, Madrid,
Spain; Fernando Bessone, Universidad Nacional de Rosario,
Rosario, Argentina; Einar Bjornsson, Division of Gastroen-
terology and Hepatology, Department of Internal Medicine,
The National University Hospital of Iceland, Reykjavik, Ice-
land; Ingolf Cascorbi, Institute for Experimental and Clinical
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RPharmacology, University Hospital Schleswig-Holstein, Kiel,
Germany; Ann K. Daly, Institute of Cellular Medicine, New-
castle University, Newcastle upon Tyne, UK; John F. Dillon,
Ninewells Hospital and Medical School, Dundee, UK; Chris-
topher P. Day, Institute of Cellular Medicine, Newcastle
University, Newcastle upon Tyne, UK; Par Hallberg, Uppsala
University, Uppsala, Sweden; Nelia Hernández, Universidad
de la Republica, Montevideo, Uruguay; Luisa Ibanez, Hos-
pital Universitari Vall d’Hebron, Barcelona, Spain; Gerd A.
Kullak-Ublick, University of Zurich, Zurich, Switzerland;
Tarja Laitinen, Helsinki University Central Hospital, Helsinki,
Finland; Dominique Larrey, Hôpital Saint Eloi, Montpellier,
France; M. Isabel Lucena, IBIMA Hospital Universitario Vir-
gen de la Victoria, Universidad de Málaga, Málaga, Spain and
CIBERehd, Madrid, Spain; Anke Maitland-van der Zee, AMC,
Amsterdam, Netherlands; Jennifer H. Martin, University of
Newcastle, Newcastle, NSW, Australia; Dick Menzies, MUHC
and McGill University, Montreal Chest Institute, Montreal,
Canada; Mariam Molokhia, King’s College, London, UK;
Munir Pirmohamed, Institute of Translational Medicine,
University of Liverpool, Liverpool, UK; Shengying Qin,
Shanghai Jiao Tong University, Shanghai, China; Mia Wade-
lius, Uppsala University, Uppsala, Sweden
DILIN investigators and coordinators can be found at
http://www.dilin.org/publications/Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/j.
gastro.2019.01.034.References
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Supplementary Methods
Genome-Wide Association Study Quality Control
for Each Cohort
Quality control was conducted at both single marker and
subject levels before performing the SNP imputation. Any
marker that did not pass the following criteria was excluded
from analysis: (1) genotype call rate in the batch of subjects
greater than 95%, (2) missing genotype rate greater than
5%, (3) P value for Hardy-Weinberg equilibrium greater
than 10–7 in controls (if applicable). Any subject who did not
pass the following criteria was excluded from analysis: (1)
missing genotype rate < 0.05 among the SNPs that passed
quality control; (2) not a sample duplicate or closely related
based on estimated identity-by-descent using PLINK v 1.07
Imputation
We used the Michigan Imputation Server1 to impute
missing genotypes separately for each ethnicity and for each
subset genotyped by the same genotyping platform. We
used the options of SHAPEIT for phasing, the Haplotype
Reference Consortium as the reference for European
ancestry samples, and the 1000 Genomes Project as the
reference for other ancestries.1–5 Imputation methods are
described in detail in the Supplementary Appendix. For HLA
genotypes, 4-digit HLA alleles were inferred using HIBAG.6
Sex chromosomes and mitochondria were not imputed. Af-
ter imputation, the resulting calls were required to have R2
> 0.6, maximum genotype posterior, and genotype miss-
ingness < 0.05 in each group and the overall cohort. Ge-
notypes were discretized based on the probability (PP) >
0.9. Variants were also removed if they were found to be
heavily influenced by genotyping chip, as determined by a
logistic regression P < .005 for a difference between 2 chip
types within the case or within the control cohort.
Icelandic Genetic Analysis
The current association analysis was done on 113 DILI
cases and 239,304 population controls using software
developed at deCODE genetics (Reykjavík, Iceland).7 Ge-
notypes of the Icelandic sample set were typed and then
imputed as previously described.7–9 The whole genomes of
15,220 Icelanders were sequenced, unveiling 40,780,213
SNPs and short indels. These variants were imputed into
151,677 Icelanders whose DNA had been genotyped with
various Illumina SNP chips and phased using long-range
phasing. Genealogical deduction of carrier status of
282,894 untyped relatives of chip-typed individuals
further increased the sample size for association analysis.
Logistic regression under an additive model was used to
test for association between variants and disease, treating
DILI as the response and expected genotype counts from
imputation as covariates. Then those samples were used
as reference for imputation of 155,250 Icelanders geno-
typed with chips. Using genealogic information, the
sequence variants were also imputed into 282,894 rela-
tives of the genotyped individuals.10 HLA alleles were
called for 28,075 Icelanders using whole-genome sequence
data and Graphtyper.11 Association testing with multiple
explanatory variables was performed using the glm
function in R.
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Supplementary Figure 2. rs2476601 allele frequency across different subsets of our cohorts. Allele frequencies by causal
drug and likelihood of DILI as described in methods. Error bars represent 95% CIs. The current stratification analysis based on
causality score has been done dividing the cases by grouping DILIN “definite and highly likely” cases and iDILIC “highly
probable” cases and grouping DILIN/iDILIC “probable” cases and grouping DILIN/iDILIC “possible” cases. PV, P value.
Supplementary Figure 1.QQ plots for (A) the overall original analysis and (B) conditional analysis.
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